Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos

In the Media

  • June 16, 2021

IntegraSyn™ – a flexible, high yield and cost-effective cannabinoid manufacturing system

InMed’s scientific team has developed IntegraSyn™ – a flexible, high yield and cost-effective manufacturing system to produce pharmaceutical-grade, bio-identical cannabinoids. InMed recently announced that IntegraSyn™ has achieved a cannabinoid yield of 5 g/L, a commercially viable yield that significantly exceeds currently reported industry yields.

How does IntegraSyn™ work?

  • IntegraSyn™ integrates well-established manufacturing processes such as biosynthesis, biotransformation and other traditional pharmaceutical manufacturing methods.
  • IntegraSyn™ optimizes use of expensive manufacturing steps, using sophisticated, but cost efficient starting materials.
  • IntegraSyn™ allows for flexibly shifting from production of one cannabinoid to a range of others, providing improved yields.
  • And IntegraSyn™ is designed to be scalable and to produce the consistent, compliant, highly pure cannabinoids required for pharmaceutical products.

As interest in the therapeutic potential of cannabinoids continues to grow, IntegraSyn™ may be the solution to provide access to a range of cost-effective, bio-identical cannabinoids.

Full Article
Source: BTV

Share this post

Latest Articles

How Could a Change in Legislation Affect the Cannabinoid Industry?

InMed’s VP, Sales & Marketing, Jerry P. Griffin, talks about how a change in legislation could impact the bioidentical cannabinoid manufacturing industry. In this interview,

Read More
May 16, 2023

BayMedica’s Bioidentical Rare Cannabinoids Fill a Market Need for Large Scale Batch-to-batch Consistency

InMed’s VP, Sales & Marketing, Jerry P. Griffin, talks about how the market for bioidentical rare cannabinoids has changed over the past year. Jerry contributes

Read More
May 8, 2023

The Dales Report: InMed’s Latest Milestones Explained

InMed CEO, Eric A. Adams, joins Shadd Dales of The Dales Report to speak about InMed’s latest milestones including the latest on the Phase 2

Read More
April 19, 2023
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent